Personalis, Inc. Financial Instrument Subject to Mandatory Redemption, Par Value Per Share
Personalis, Inc. (PSNL) had Financial Instrument Subject to Mandatory Redemption, Par Value Per Share of $5.07 per share as of 2024-08-31, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Other Liabilities and Financial Instruments Subject to Mandatory Redemption
us-gaap:FinancialInstrumentSubjectToMandatoryRedemptionParValuePerShare · last filed 2024-11-06
- 2024-08-31: Financial Instrument Subject to Mandatory Redemption, Par Value Per Share $5.07.
| Period end | Financial Instrument Subject to Mandatory Redemption, Par Value Per Share |
|---|---|
| 2024-08-31 | $5.07 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |